Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

NCT07318831 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma (NB)
Neuroblastoma in Children

Interventions

DRUG: Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide

Sponsor

Tianjin Medical University Cancer Institute and Hospital